178 related articles for article (PubMed ID: 7473144)
1. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
[TBL] [Abstract][Full Text] [Related]
2. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
3. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
[TBL] [Abstract][Full Text] [Related]
4. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
5. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
[TBL] [Abstract][Full Text] [Related]
7. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR
J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495
[TBL] [Abstract][Full Text] [Related]
8. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
9. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
[TBL] [Abstract][Full Text] [Related]
10. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
12. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
[TBL] [Abstract][Full Text] [Related]
13. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
Ganellin CR; Fkyerat A; Bang-Andersen B; Athmani S; Tertiuk W; Garbarg M; Ligneau X; Schwartz JC
J Med Chem; 1996 Sep; 39(19):3806-13. PubMed ID: 8809168
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
15. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
[TBL] [Abstract][Full Text] [Related]
16. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
17. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
19. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
[TBL] [Abstract][Full Text] [Related]
20. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
